BR112018007173A2 - métodos e composições para prevenir ou tratar câncer - Google Patents

métodos e composições para prevenir ou tratar câncer

Info

Publication number
BR112018007173A2
BR112018007173A2 BR112018007173A BR112018007173A BR112018007173A2 BR 112018007173 A2 BR112018007173 A2 BR 112018007173A2 BR 112018007173 A BR112018007173 A BR 112018007173A BR 112018007173 A BR112018007173 A BR 112018007173A BR 112018007173 A2 BR112018007173 A2 BR 112018007173A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
preventing
treating cancer
elephant
Prior art date
Application number
BR112018007173A
Other languages
English (en)
Other versions
BR112018007173B1 (pt
Inventor
Schiffman Joshua
Schroeder Avi
Abegglen Lisa
Original Assignee
Technion Research & Development Foundation Ltd
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research & Development Foundation Ltd, University Of Utah Research Foundation filed Critical Technion Research & Development Foundation Ltd
Publication of BR112018007173A2 publication Critical patent/BR112018007173A2/pt
Publication of BR112018007173B1 publication Critical patent/BR112018007173B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente divulgação é dirigida a métodos e composições para inibir uma célula cancerosa usando sequências de ácido nucleico que codificam p53 de elefante ou sequências de aminoácido de p53 de elefante.
BR112018007173-0A 2015-10-08 2016-10-07 composição compreendendo àcidos nucléicos ou proteínas p53 de elefante e uso da composição para inibir câncer BR112018007173B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562239103P 2015-10-08 2015-10-08
US62/239,103 2015-10-08
US201662379179P 2016-08-24 2016-08-24
US62/379,179 2016-08-24
PCT/US2016/055921 WO2017062726A1 (en) 2015-10-08 2016-10-07 Methods and compositions for preventing or treating cancer

Publications (2)

Publication Number Publication Date
BR112018007173A2 true BR112018007173A2 (pt) 2018-10-16
BR112018007173B1 BR112018007173B1 (pt) 2021-02-02

Family

ID=58488561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007173-0A BR112018007173B1 (pt) 2015-10-08 2016-10-07 composição compreendendo àcidos nucléicos ou proteínas p53 de elefante e uso da composição para inibir câncer

Country Status (15)

Country Link
US (3) US10709761B2 (pt)
EP (1) EP3359197B1 (pt)
JP (1) JP6599566B2 (pt)
KR (1) KR102304533B1 (pt)
CN (1) CN109069644B (pt)
AU (1) AU2016335701B2 (pt)
BR (1) BR112018007173B1 (pt)
CA (1) CA3001054C (pt)
ES (1) ES2863773T3 (pt)
IL (1) IL258512B (pt)
MX (1) MX2018004187A (pt)
RU (1) RU2718499C2 (pt)
SG (1) SG11201803768WA (pt)
WO (1) WO2017062726A1 (pt)
ZA (1) ZA201802268B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649255A4 (en) * 2017-07-06 2021-03-17 Barcode Diagnostics Ltd. METHODS FOR PRE-SCREENING THERAPEUTIC AGENTS IN BODY FLUIDS
WO2020234871A1 (en) * 2019-05-20 2020-11-26 Technion Research & Development Foundation Limited Metabolite encapsulating nanoparticles to enhance cellular cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
JP2001522871A (ja) 1997-11-19 2001-11-20 ジョージタウン・ユニバーシティ 標的化リポゾーム遺伝子送達
US6831155B2 (en) * 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US20100143358A1 (en) 2007-01-22 2010-06-10 The United States Government As Represented By The Department Of Veterans Affairs Use of Antibody Conjugates
WO2009009587A2 (en) 2007-07-09 2009-01-15 Board Of Regents Of The University Of Nebraska Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
WO2009090049A1 (en) * 2008-01-14 2009-07-23 European Molecular Biology Laboratory Peptides for the specific binding and regulation of protein targets
EP2282776A4 (en) 2008-04-11 2011-11-09 Lsip Llc INDUCER OF APOPTOSIS
EP2717901A4 (en) * 2011-06-06 2015-01-21 Women And Infants Hospital Of Rhode Island HE4-BASED THERAPY FOR MALIGNINE DISEASES
CN104208066B (zh) * 2013-06-03 2016-06-15 中国科学院遗传与发育生物学研究所 哌嗪衍生物作为p53分子调节剂的用途

Also Published As

Publication number Publication date
RU2018116896A (ru) 2019-11-11
MX2018004187A (es) 2019-01-21
EP3359197B1 (en) 2021-03-10
EP3359197A4 (en) 2019-04-10
CA3001054C (en) 2021-12-14
RU2018116896A3 (pt) 2019-11-11
US20200368316A1 (en) 2020-11-26
US11833188B2 (en) 2023-12-05
CA3001054A1 (en) 2017-04-13
KR102304533B1 (ko) 2021-09-28
WO2017062726A1 (en) 2017-04-13
BR112018007173B1 (pt) 2021-02-02
CN109069644A (zh) 2018-12-21
AU2016335701A1 (en) 2018-05-10
KR20180086188A (ko) 2018-07-30
RU2718499C2 (ru) 2020-04-08
IL258512A (en) 2018-05-31
US10709761B2 (en) 2020-07-14
SG11201803768WA (en) 2018-06-28
ES2863773T3 (es) 2021-10-11
JP2018534357A (ja) 2018-11-22
EP3359197A1 (en) 2018-08-15
IL258512B (en) 2021-07-29
ZA201802268B (en) 2019-01-30
US20190070259A1 (en) 2019-03-07
CN109069644B (zh) 2022-10-28
US20240016890A1 (en) 2024-01-18
JP6599566B2 (ja) 2019-10-30
AU2016335701B2 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018013065A2 (pt) composições e métodos para o tratamento de hemoglobinopatias
BR112018004620A2 (pt) moduladores da expressão de kras
CL2018001181A1 (es) Inhibidores de ret
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
SG11201704936SA (en) Corrosion inhibitor compositions for acidizing treatments
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
UY37018A (es) Inhibidores bicíclicos de pad4
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
CR20170005A (es) Derivados de insoindolina
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
EA201891628A1 (ru) Ингибирование аллергической реакции с использованием ингибитора il-33
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2016, OBSERVADAS AS CONDICOES LEGAIS.